Wegovy Constipation: STEP-1 Rates, Mechanism & Evidence-Based Relief Protocol

Constipation is one of the most common GI side effects on Wegovy after nausea and diarrhea. The STEP-1 pivotal trial of semaglutide 2.4 mg for chronic weight management reported constipation in 24.2% of patients on Wegovy vs. 11.5% on placebo over 68 weeks^[2]. The mechanism is the same one that suppresses appetite: GLP-1 receptor activation slows gastric emptying and reduces overall GI motility — and at the 2.4 mg obesity dose, that deceleration is more profound than at the 1 mg Ozempic diabetes dose^[7]. This guide covers what STEP-1, STEP-4, and SELECT actually reported, why Wegovy produces more constipation than Ozempic, when symptoms peak and resolve, the evidence-based relief protocol, and the red-flag warning signs that mean stop self-managing and call your prescriber immediately.

The honest short answer

If you started Wegovy a few weeks ago and bowel movements have gone from daily to every 3-5 days, that’s the textbook semaglutide 2.4 mg pattern. STEP-1 reported constipation in 24.2% of patients on Wegovy 2.4 mg vs. 11.5% on placebo over 68 weeks of treatment, with most cases mild-to-moderate and the typical episode lasting days to a few weeks rather than the entire treatment duration^[2]. STEP-4 and SELECT confirm the rate persists across maintenance and cardiovascular-event populations^[3][4]. For most patients this resolves with a deliberate fiber-fluid-walking protocol layered on from day one of titration, not improvised in week six when you’re already miserable. The red flag — no stool for 5+ days plus abdominal pain or vomiting — warrants an immediate call to your prescriber, not another laxative.

What STEP-1, STEP-4, and SELECT actually measured

STEP-1 was the 68-week pivotal phase 3 trial of semaglutide 2.4 mg (Wegovy) for chronic weight management in 1,961 adults with obesity or overweight plus weight-related comorbidities. The Wilding 2021 NEJM publication reported constipation as one of the most common adverse events in the active arm^[2]:

• Semaglutide 2.4 mg (Wegovy) — 24.2% constipation over 68 weeks.
• Placebo arm — 11.5% constipation as the background rate.
• Drug-attributable signal — roughly 12.7 percentage points above placebo, the second-highest GI signal after nausea (44.2% vs 16.1%).

STEP-4 extended the question into maintenance: after 20 weeks of open-label semaglutide lead-in titration, 803 patients who reached the 2.4 mg maintenance dose were randomized to continued semaglutide or switched to placebo for an additional 48 weeks. Constipation continued to be reported on the active arm at rates consistent with the STEP-1 maintenance phase, while the switch-to-placebo arm showed the expected resolution of GI adverse events as the drug washed out^[3]. The implication is direct: semaglutide’s motility effect persists as long as you remain on the drug, so the constipation-management habits need to be permanent, not time-limited.

SELECT, the 17,604-patient cardiovascular-outcomes trial of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity (without diabetes), provides the largest and longest-duration safety dataset for Wegovy dosing. The Lincoff 2023 NEJM publication reported GI adverse events including constipation occurring more frequently on semaglutide than placebo across the mean 39.8-month follow-up, with the rates and discontinuation patterns broadly consistent with the STEP program^[4]. SELECT is the definitive evidence that the GI signal is real, durable, and present in a non-diabetic obesity population over multiple years — not an artifact of short registration trials.

The Wegovy FDA label Section 6.1 pools the constipation rates across the registration trials and reports figures consistent with STEP-1^[1]. Section 5.6 Acute Kidney Injury and Section 5.4 Acute Pancreatitis are the two FDA-labeled warnings that matter most for constipation management decisions — both are discussed in the relief and red-flags sections below.

Why Wegovy 2.4 mg produces more constipation than Ozempic 2.0 mg

Semaglutide is the active ingredient in both Wegovy (2.4 mg max for chronic weight management) and Ozempic (2.0 mg max for type 2 diabetes). Same molecule. The reason Wegovy produces substantially more constipation than Ozempic comes down to two factors: exposure and indication.

On exposure: GLP-1 receptor agonist effects on gastric emptying are dose-dependent. Marathe and colleagues’ 2013 review in Peptides summarized the physiology: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon^[7]. The 2.4 mg weekly maintenance dose produces roughly 20% higher exposure than the 2.0 mg maintenance dose used at the top of the Ozempic range — small in pharmacokinetic terms, but enough to meaningfully shift the GI side-effect profile because the dose-response curve for gut motility is steep in the therapeutic range.

On indication: the Ozempic FDA label Section 6.1 reports constipation in roughly 3.1% of patients on the 1 mg diabetes dose, and SUSTAIN-1 reported approximately 5% on 1 mg over 30 weeks^[5]. STEP-1 reports 24.2% on Wegovy 2.4 mg over 68 weeks — roughly eight times the Ozempic 1 mg rate. Part of this gap is dose; part is exposure duration (68 weeks vs 30 weeks gives more time for cumulative adverse events to be reported); and part is population (obesity-trial patients on a higher-dose escalation schedule report symptoms differently than diabetes-trial patients on slower titration). The bottom line: don’t generalize Ozempic tolerance to Wegovy. The 2.4 mg dose is meaningfully harder on the gut.

For the head-to-head Wegovy vs. Ozempic comparison across the full adverse-event profile, see our Ozempic constipation article sister piece — the Ozempic rates and management protocol are otherwise identical because it’s the same molecule.

Three additional factors stack on top of the direct motility effect:

• Lower food volume — Wegovy delivers the largest mean weight loss of any commercially available single-agonist GLP-1, which means patients eat substantially less than before. Less food intake means less fiber and less stool bulk. A 1,200-calorie day with no deliberate fiber focus often delivers under 10g of fiber, well below the 25-35g/day adult target.
• Lower fluid intake — satiety on Wegovy extends to thirst for many patients. Sipping water all day takes conscious effort once the prompt-to-drink-with-meals is gone.
• Concurrent antiemetics — if you’re using ondansetron (Zofran) for the nausea component, that drug itself causes constipation, and the two effects stack badly. See our nausea management guide for the antiemetic trade-off discussion.

When Wegovy constipation peaks and resolves

Unlike nausea, which is concentrated in the first 1-2 weeks after each dose step, constipation has a different temporal pattern. In STEP-1 and STEP-4, GI adverse events were reported as cumulative incidences over the 68-week treatment periods, with constipation building gradually rather than spiking around each titration^[2][3]. The pattern most prescribers see in practice on the standard 16-week Wegovy titration (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg):

• Weeks 1-4 (titration to 0.25 and 0.5 mg) — constipation builds gradually as gut transit slows and food/fluid intake drops. Many patients don’t notice until they realize they haven’t had a bowel movement in 3-4 days.
• Weeks 5-12 (titration through 1 mg and 1.7 mg) — constipation often peaks during this window. Hard, dry stools and infrequent bowel movements (every 3-5 days) are the typical report, especially around the 1 mg and 1.7 mg dose steps when the gut hasn’t yet adapted.
• Months 4-6 (2.4 mg maintenance reached) — the gut adapts to the slowed motility for most patients. Many report bowel habits stabilizing at a new normal — less frequent than baseline but more predictable. A subset of patients on 2.4 mg experience persistent constipation through year one.
• Long-term maintenance — STEP-4 reported that GI adverse events including constipation continued at low rates through 68 weeks of continued semaglutide vs. a clear drop after switching to placebo, suggesting the motility effect persists as long as you’re on the drug^[3]. SELECT confirmed the pattern across a mean 39.8 months of follow-up^[4].

The takeaway: don’t wait until you’re miserable. Start the fiber, fluid, and walking habits from day one of titration, not after week four when you’re already struggling. For the full side-effect timeline by drug and week, our GLP-1 side effect timeline tool renders the STEP-1, SURMOUNT-1, and SUSTAIN-1 data interactively.

Practical relief protocol: fiber, fluids, walking

The first-line relief protocol is conservative and well-supported. It costs nothing, has no drug interactions, and is what most gastroenterologists recommend before any laxative.

Soluble fiber 25-35g/day

On a 1,200-1,500 calorie Wegovy day, hitting 25-35g of fiber requires deliberate planning — you cannot get there by accident on a typical Western reduced-calorie diet. Soluble fiber (psyllium, oat beta-glucan, fruit pectin) shows the most consistent effect on constipation in randomized trials because it forms a transit- lubricating gel that softens stool and accelerates colonic motility.

• Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1-3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation.
• Ground flaxseed — 1-2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
• Chia seeds — 1-2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
• High-fiber whole foods — raspberries (8g per cup), pears with skin (5-6g each), avocado (10g each), lentils (15g per cup cooked), black beans (15g per cup), bran cereal (10g+ per serving).

Use our GLP-1 fiber calculator to plan a day that actually hits 25-35g; without planning, most Wegovy patients land between 8-12g.

Hydration 2.5-3L/day

Fiber without enough fluid is a worse outcome than no fiber. Insoluble fiber needs water to soften stool; soluble fiber needs water to form the gel that lubricates transit. The standard recommendation for an adult on Wegovy is 2.5-3 liters of non-caffeinated fluid per day — this is also the volume that protects against the FDA-label acute kidney injury risk (see What NOT to do below)^[1].

Practical patterns that work:

• A 24 oz water bottle next to you all day, refilled three times (totals ~2.1L).
• A full 8 oz glass with each medication or supplement.
• Herbal tea or sparkling water counts toward fluid totals. Coffee counts but is mildly dehydrating at high doses; the net is still positive for most people.

Walking and gentle movement

Physical activity stimulates colonic motility. A 20-30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. The morning is particularly effective because the gastrocolic reflex (colon waking up after the first meal of the day) is the strongest intrinsic peristaltic signal you have.

Pelvic-floor mechanics matter too. Squatting (or using a footstool like a Squatty Potty under the feet during a bowel movement) changes the anorectal angle and reduces the straining required — particularly helpful when stool is harder than usual on Wegovy.

Dose-stability discipline

The Wegovy titration schedule (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 weeks) exists specifically to let the gut adapt to each exposure increment before the next one. Patients who skip titration steps, restart at a higher dose after a gap, or push to 2.4 mg faster than the label schedule report substantially more constipation. If you’re struggling at a given step, ask your prescriber about pausing escalation at the current dose for an extra 4 weeks rather than pushing through. The Wegovy FDA label permits delayed titration explicitly for GI intolerance^[1].

Second-line: magnesium citrate, osmotic laxatives, stool softeners

If the first-line measures aren’t enough after 7-10 days of consistent effort, second-line options are appropriate. Discuss with your prescriber before starting anything if you have kidney disease, heart failure, or are on multiple other medications.

Magnesium citrate 200-400 mg

Magnesium acts as an osmotic laxative in the colon — it pulls water into the bowel lumen, softening stool and accelerating transit. Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days^[8]. Magnesium citrate is the better-absorbed form for daily use; magnesium oxide is the form studied in the Mori RCT.

• Starting dose — 200 mg magnesium citrate at bedtime. Titrate up to 400 mg if needed and tolerated.
• Side effects — loose stools or diarrhea if you overshoot. Drop the dose if this happens.
• Contraindications — kidney disease (CKD stage 3+), since impaired kidneys can’t excrete excess magnesium. Check with your prescriber if you have any renal impairment.

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.

Stool softeners (docusate)

Docusate is less effective than osmotic laxatives in randomized trials but can help if your main issue is hard, dry stool rather than infrequency. 100 mg twice daily is the standard dose.

Stimulant laxatives (senna, bisacodyl) — short-term only

Stimulant laxatives work but should be used sparingly — nightly use over weeks-months can lead to dependence in some patients. Reasonable as a 2-3 night rescue when other measures haven’t produced a bowel movement in 4-5 days. Not a long-term strategy.

Red flags: when to call your prescriber

The Wegovy FDA label includes ileus as a postmarketing adverse reaction reported in patients on semaglutide^[1]. Ileus — the functional shutdown of normal bowel peristalsis — can mimic ordinary Wegovy constipation in its early presentation but progresses to a medical emergency. The distinguishing features:

• No bowel movement for 5+ days AND no passage of gas (this is the cardinal sign — obstipation is more concerning than just constipation).
• Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
• Severe abdominal pain, especially crampy or colicky pain in waves.
• Vomiting, particularly vomiting of bile (green/ yellow) or feculent (foul-smelling, dark) material.
• Inability to keep down fluids.

Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your medication or the label so the treating team knows you’re on semaglutide 2.4 mg. Ileus and bowel obstruction can require nasogastric decompression, IV fluids, and in severe cases surgical intervention. The condition is uncommon but the consequences of missing it are serious.

For the broader differential between ileus, gastroparesis, and ordinary GLP-1 delayed emptying, see our GLP-1 side effects: what trials actually showed article. Pancreatitis (Wegovy FDA label Section 5.4) is another rare but serious consideration that overlaps with severe GI symptoms^[1]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom.

How Wegovy compares to Ozempic on constipation (same molecule, higher dose)

Patients on the Ozempic 1 mg diabetes dose who switch to Wegovy 2.4 mg for weight loss are usually surprised by how much harder Wegovy is on the gut. The trial data quantify the gap:

• Wegovy 2.4 mg (STEP-1) — 24.2% constipation over 68 weeks vs 11.5% placebo^[2].
• Semaglutide 1 mg (SUSTAIN-1) — approximately 5% over 30 weeks^[5].
• Semaglutide 0.5-1 mg (Ozempic FDA label pooled) — approximately 3.1% vs 1.5% placebo across the pooled diabetes registration trials.

Roughly an eight-fold gap between the Ozempic diabetes dose and the Wegovy obesity dose. Part is dose (2.4 mg vs 1 mg), part is exposure duration (68 weeks vs 30 weeks), part is the obesity-trial titration schedule pushing patients faster to maintenance. None of these factors generalize Ozempic tolerance to Wegovy. If your dominant Ozempic side effect was none-or-mild constipation, expect Wegovy to deliver a substantially heavier hit during titration. Plan proactively: start the fiber, fluid, and walking habits the day your first 0.25 mg dose ships, not after week four.

How Wegovy compares to Zepbound/tirzepatide on constipation

Patients deciding between Wegovy and Zepbound often ask which has the easier GI profile. On constipation specifically, the cross-trial comparison (not head-to-head) favors tirzepatide:

• Wegovy 2.4 mg (STEP-1) — 24.2% constipation over 68 weeks^[2].
• Tirzepatide 15 mg (SURMOUNT-1) — 11.7% constipation over 72 weeks^[6].
• Tirzepatide 10 mg (SURMOUNT-1) — 6.4% constipation^[6].

Roughly half the constipation rate at top weight-loss doses. Two caveats apply. First, the trials measured constipation as patient-reported AEs with different prompts and adjudication, so the comparison is not head-to-head and the absolute numbers should be read as order-of-magnitude rather than precise. Second, the GI side-effect mix differs between the two drugs: tirzepatide trends toward more diarrhea than semaglutide at comparable weight-loss exposure. The practical implication for patients already weighing a switch: if your dominant problem on Wegovy is constipation, tirzepatide may offer real relief but at the cost of higher diarrhea risk; the better lever is usually the fiber-fluid-magnesium protocol on whichever drug you’re already on. See our Zepbound constipation and tirzepatide constipation articles for the full SURMOUNT-1 and Zepbound FDA-label breakdown.

What NOT to do (FDA dehydration + AKI warning)

The Wegovy FDA label Section 5.6 contains an explicit warning about acute kidney injury^[1]: postmarketing reports document AKI — sometimes requiring hemodialysis — in patients on semaglutide, frequently associated with the dehydration that follows persistent nausea, vomiting, diarrhea, or reduced fluid intake. The label specifically instructs prescribers to advise patients on hydration and to monitor renal function when starting or escalating the drug.

Implications for constipation management:

• Don’t megadose osmotic laxatives. A double or triple dose of PEG 3350 or magnesium citrate can induce diarrhea, which combined with reduced GLP-1-driven thirst can drive you into the dehydration-AKI zone the FDA label warns about. Use the recommended doses and titrate gradually.
• Don’t use bowel preps as constipation treatment. A polyethylene glycol bowel prep (4 liters of GoLYTELY or similar) is designed to empty the colon for colonoscopy — it’s not a constipation remedy. The fluid shift is dangerous in a dehydrated patient.
• Don’t skip fluids to “reduce bloating” . Some patients try to fight the bloating component of constipation by drinking less. This is exactly backward and is the fastest path to AKI.
• Don’t add high-dose magnesium if you have kidney disease. CKD stage 3+ patients can develop hypermagnesemia (toxic blood magnesium levels) from oral supplements that healthy kidneys would excrete. Confirm with your prescriber.
• Don’t take stimulant laxatives nightly for weeks. Dependence is a real outcome with chronic stimulant use. Use them as a 2-3 night rescue, not a daily habit.
• Don’t ignore the ileus red flags. The most dangerous mistake is assuming “it’s just my Wegovy constipation” when the pattern has shifted to obstipation, distension, and vomiting. When in doubt, call.

Related research and tools

• Ozempic constipation: causes, FDA-label rates, and evidence-based relief — the sister article for the diabetes-dose semaglutide brand, covering SUSTAIN-1 and Ozempic FDA-label rates
• Zepbound constipation: SURMOUNT-1 rates, mechanism, and relief — the dual-agonist tirzepatide alternative with the SURMOUNT trial data
• Tirzepatide constipation: FDA-label rates and evidence-based relief — the cross-indication tirzepatide companion
• GLP-1 nausea: the practical management guide — the trial rates, timeline, and management tactics for the other major GI side effect
• GLP-1 side effects: what the trials actually showed — the comprehensive trial-by-trial side-effect table
• GLP-1 side effect questions answered — the Q&A hub with every common patient question
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week
• GLP-1 fiber calculator — plan a 25-35g/day fiber target on a reduced-calorie Wegovy day

Important disclaimer. This article is educational and does not constitute medical advice. Constipation management decisions should always be made with your prescribing clinician, particularly if you have chronic kidney disease, heart failure, or are taking multiple other medications. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.